Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth
TORONTO, ONTARIO July 27, 2022 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine and psilocybin treatments for people living with depression and related mental health disorders, is pleased to announce the addition of Jason Wolkove, Chief Information Officer and Daniel Herrera, Vice President, Research & Development and Growth. These strategic hires bolster Braxia’s senior leadership team and its ability to drive growth and innovation. Both roles will be integral to executing the expansion of the Company’s clinical footprint, the rollout and expansion of novel ketamine and psilocybin therapy offerings, new special access programs, current and upcoming clinical trials, and the potential commercialization of future product development. Braxia’s new Chief Information Officer, Jason Wolkove, is a seasoned technology executive bringing more than 20 years of experience growing complex...